Impact of Wellbutrin XL, Vyvanse, and Seroquel on Cortisol Levels
Quetiapine (Seroquel) significantly reduces cortisol levels, bupropion (Wellbutrin XL) does not consistently change cortisol in most patients, and lisdexamfetamine (Vyvanse) increases cortisol levels as expected with stimulant medications.
Quetiapine (Seroquel): Cortisol Reduction
Quetiapine demonstrates the most robust effect on cortisol among these three medications, consistently lowering both ACTH and cortisol secretion. In a controlled study of healthy volunteers, quetiapine significantly reduced both ACTH (p ≤ 0.002) and cortisol (p ≤ 0.005) compared to placebo 1. This effect was dose-dependent, with both 25 mg and 100 mg doses significantly reducing nocturnal urinary cortisol excretion (p < 0.0005) 2.
The mechanism appears related to quetiapine's blockade of serotonergic receptors, though adrenergic and histaminergic receptor blockade may also contribute 1. This HPA-axis downregulation persists under both normal and stress conditions, with no interaction effect observed during acoustic stress testing 2.
Clinical Implications for Seroquel
- The cortisol-lowering effect may contribute to quetiapine's efficacy in treating depressive symptoms and improving cognitive function
- This effect occurs independently of stress conditions
- The reduction is consistent across different doses
Bupropion (Wellbutrin XL): Variable Effects
Bupropion shows inconsistent effects on cortisol that may predict treatment response. In depressed patients, treatment non-responders showed a significant increase in nocturnal urinary free cortisol (NUFC) after a single 150 mg dose, while responders showed no change 3. Critically, 8 weeks of bupropion treatment did not reduce HPA activity in either responders or non-responders 3, distinguishing it from most other antidepressants.
However, one pediatric study found that bupropion increased DHEA-S levels without significantly changing cortisol levels in boys with ADHD after 12 weeks 4.
Key Distinction for Wellbutrin
- Unlike SSRIs and other antidepressants that typically reduce cortisol, bupropion does not consistently lower HPA axis activity
- The acute cortisol response to bupropion may have predictive value for treatment efficacy
- The mechanism likely involves dopaminergic and/or noradrenergic pathways rather than serotonergic ones
Lisdexamfetamine (Vyvanse): Cortisol Elevation
Psychostimulant medications, including lisdexamfetamine, are associated with increased basal cortisol levels or no change 5. This represents the opposite effect compared to antipsychotics and most antidepressants. The cortisol elevation is consistent with stimulants' sympathomimetic properties and activation of the HPA axis.
Clinical Context for Vyvanse
- The cortisol increase is an expected pharmacologic effect of stimulant medications
- This effect should be considered when interpreting cortisol measurements in patients taking Vyvanse
- The clinical significance of this elevation in routine ADHD treatment remains unclear
Summary of Comparative Effects
Ranked by magnitude of cortisol impact:
- Quetiapine (Seroquel): Strong reduction in cortisol and ACTH
- Lisdexamfetamine (Vyvanse): Increase in basal cortisol
- Bupropion (Wellbutrin XL): Minimal to no consistent effect on cortisol
Important Caveats
- These cortisol effects should be considered when ordering cortisol testing for endocrine evaluation in patients taking these medications
- The clinical significance of cortisol changes varies by indication—quetiapine's cortisol reduction may be therapeutically beneficial in mood disorders but is not the primary mechanism of action
- Combination therapy with these medications could produce complex, unpredictable effects on HPA axis function
- Most evidence comes from short-term studies; long-term effects on cortisol regulation require further investigation